ReviewACS omega2025
Advancing Drug Delivery: Design and Applications of MOF-Polyurethane Composites for Controlled Release Systems.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanodelivery of Gentiopicroside for Inflammatory Skin Lesions: Insights from Psoriasis and Diabetic Foot Ulcers.International journal of nanomedicine · 2026Review
- Investigation of the loading and release behavior of paracetamol, mesalazine, and carbamazepine utilizing Cu-and Zn(BDC) MOFs.Scientific reports · 2025Article
- Multifunctional Nanomaterial-Integrated Hydrogels for Sustained Drug Delivery: From Synthesis and Characterization to Biomedical Application.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The design and development of controlled-release drug systems represent a pivotal area of research in modern pharmaceutical technologies. An ideal drug release system should precisely regulate both the release rate and duration of the drug, thereby enhancing therapeutic efficacy, reducing dose frequency, and minimizing adverse effects. In recent years, nanomaterials have become integral to drug delivery, with nanotechnology focusing on the design and application of nanomaterials. Metal-organic frameworks (MOFs) have emerged as promising drug carriers due to their high specific surface area, tunable porosity, and selective adsorption capabilities. However, MOFs often exhibit limited thermal stability, susceptibility to degradation, and sensitivity to acidic and basic conditions. To address these limitations, the integration of MOFs with polymers has shown promising potential. MOF-polymer composites can enhance drug loading capacity, improve drug solubility, and provide greater thermal stability while mitigating adverse reactions. Polyurethane (PU) is widely employed as a drug carrier due to its unique chemical properties and biodegradability. However, PU alone may lead to issues such as burst drug release and vulnerability to fungal colonization. Consequently, MOF-PU composites have garnered significant attention as advanced drug carriers, leveraging the synergistic properties of both materials to overcome their individual limitations. This review explores the definition, preparation methods, advantages, and application domains of MOF-PU composites, with a particular emphasis on their role as drug carriers. The objective is to provide a comprehensive reference for ongoing and future research into the utilization of MOF-PU composites in drug delivery systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.